MRK and MKKGY Related Headlines
Go Back- MilliporeSigma Announces Opening of BioReliance® Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe
- FDA grants breakthrough designation to EMD Serono's lupus drug enpatoran
- EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients with Active Skin Manifestations
- EMD Serono names new global commercial head and North America president
- EMD Serono Announces Healthcare Leadership Changes for Global Commercial Strategy and North America
- Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
- MilliporeSigma Appoints New Heads of Discovery Solutions and Strategy & Business Development
- Merck KGaA begins phase 3 trial for colorectal cancer drug
- Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
- MilliporeSigma Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
- Merck KGaA begins phase 3 lupus skin treatment trial
- Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
- MilliporeSigma Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography
- EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities
- FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
- EMD Serono Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis
- MilliporeSigma Partners with Promega to Advance 3-D Cell Drug Discovery Technologies
MRK and MKKGY Related Press Releases
Go Back- MilliporeSigma Announces Opening of BioReliance® Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe
- EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients with Active Skin Manifestations
- EMD Serono Announces Healthcare Leadership Changes for Global Commercial Strategy and North America
- Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
- MilliporeSigma Appoints New Heads of Discovery Solutions and Strategy & Business Development
- Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
- MilliporeSigma Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
- Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
- MilliporeSigma Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography
- EMD Serono Advances Patient Access to IVF Medicines in the U.S., Aligned with National Health Priorities
- FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
- EMD Serono Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis
- MilliporeSigma Partners with Promega to Advance 3-D Cell Drug Discovery Technologies
